학술논문
What is the association of polypharmacy with frailty in heart failure? A systematic review and meta-analysis.
Document Type
Academic Journal
Author
Prokopidis K; Department of Musculoskeletal Science & Ageing, University of Liverpool, Liverpool, United Kingdom.; Testa GD; Department of Geriatric and Intensive Care Medicine, Careggi Hospital, University of Florence, Florence, Italy.; Veronese N; Unit of Geriatrics, Department of Internal Medicine and Geriatrics, University of Palermo, Palermo, Italy.; Dionyssiotis Y; 2 Physical Medicine and Rehabilitation Department, National Rehabilitation Center EKA, Athens, Greece.; McLean J; Androlabs, London, United Kingdom.; Walker LE; Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom.; Department of Pharmacology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, United Kingdom.; Sankaranarayanan R; Department of Pharmacology, Institute of Systems, Molecular and Integrative Biology, University of Liverpool, United Kingdom.; Liverpool Centre for Cardiovascular Science, Liverpool Heart & Chest Hospital, Liverpool, United Kingdom.; Faculty of Health and Life Sciences, University of Liverpool, Liverpool, United Kingdom.
Source
Publisher: Hylonome Publications Country of Publication: Greece NLM ID: 101756655 Publication Model: eCollection Cited Medium: Internet ISSN: 2459-4148 (Electronic) Linking ISSN: 24594148 NLM ISO Abbreviation: J Frailty Sarcopenia Falls Subsets: PubMed not MEDLINE
Subject
Language
English
Abstract
This systematic review and meta-analysis aimed to explore the differences in the number of prescribed medications and polypharmacy risk between patients with heart failure (HF) and frailty vs. those with HF but without frailty. Eligible studies included observational or experimental studies in patients aged ≥50 years. Thirteen studies met the criteria and were included in the final analysis. Patients with frailty and HF exhibited a higher risk of polypharmacy (OR: 1.87, 95% CI 1.72 - 2.04, I 2 = 0%, P < 0.01) compared to those without frailty. Results remained significant after adjusting for comorbidity status. Additionally, patients with frailty and HF were prescribed more medications compared to those without ( k = 6; MD: 1.43, 95% CI 0.31 - 2.55, I 2 = 94%, P = 0.01), with a high degree of heterogeneity. However, results were non-significant after adjustment for comorbidity status. Patients with HF and frailty have a higher need of polypharmacy compared to those without frailty, which may increase the risk of potentially inappropriate medications (PIM). Investigating the real-world prevalence of PIM may support clinicians in their routine assessment as part of a comprehensive management strategy in patients with HF and frailty.
(Copyright: © 2024 Hylonome Publications.)
(Copyright: © 2024 Hylonome Publications.)